Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in IXI?

IXICO trading ahead of expectations as digital tech permeates neuroscience sector

IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
mri scanner
The company's technology manages and helps interpret images from MRI and positron emission tomography as well as collating and making sense of biosensor data

A recent run of contract wins for IXICO Plc (LON:IXI) reveals a growing adoption of digital technologies in medical imaging it uses to support clinical trials of new medicines in neuroscience.

The latest contract, in September, was worth £9.1mln to provide insight from magnetic resonance imaging (MRI) data to assist in a Phase III clinical trial for a drug to treat Huntington's disease.

Huntington’s is one of five neurological disease therapeutic areas in which it is actively supporting the hunt for breakthrough treatments, having already landed contracts from companies active in Alzheimer’s, Parkinson’s, PSP (progressive supranuclear palsy), and MS.

Focused on neuroscience

“Neurological disease represents a major unmet medical need”, says Giulio Cerroni, chief executive, adding that the company is seeing growing demand for its services.

Macro trends such as an ageing population, coupled with there being very few medicines available for these debilitating and potentially life-limiting diseases, is driving increased investment in the neuroscience drug discovery and development pipeline from big pharmaceutical and bioscience companies.

This latest contract win is IXICO’s fourth announced this year for Huntington’s – a genetic disorder which is inherited and causes brain cell death and can degrade mental and physical abilities. 

“The core of our strategy is expertise, we have to be the ‘go to’ people for analysis of medical images in the brain”, Cerroni adds.

Financial numbers have started to reflect the growing interest.

WATCH: IXICO full year performance expected to be 'ahead of market expectations'

In August, the group forecast revenue growth this year of nearly 25% or at least £5.1mln, while losses will also be significantly reduced.

What it does

IXICO’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI and positron emission tomography (PET) scanners as well as collating and making sense of Real World data from wearable biosensors.

Biogen collaboration

But the IXICO business model is far subtler than simply being a digital pharma services business to clinical trials.

Its collaboration with the giant Biogen is illustrative of this.

It is providing the digital platform to connect physicians treating patients with multiple sclerosis with neuroradiology expertise to enable them to reliably detect and monitor the safety of the company’s flagship product, Tysabri.

While it is a hugely effective treatment, there is a small risk an increased incidence of infection with JC polyomavirus in the brain which can lead to progressive multifocal leukoencephalopathy or PML.

PML is a serious condition that ultimately can result in serious disability or even death.

IXICO’s technology helps spot the signs of potential PML infection early and differentiate it from signs of MS disease activity, providing the physician with a second opinion and help them determine if the patient should continue with Tysabri treatment.

For Biogen this offers a huge boon – it is a way of keeping tabs on patients and it means more people can be safely put on the MS drug than are currently receiving it.

Crossing the Rubicon

In providing such a drug safety monitoring service, IXICO has crossed the commercial Rubicon (if one can actually do that).

It has taken a useful piece of technology deployed in the clinical development of drugs and developed a companion product that will help doctors prescribe drugs more effectively.

Now, this is a hot area, one potentially worth tens of billions of pounds when it is fully developed and IXICO’s strategy is quite simple – it wants a small slither of the pie.

It is using the technology backbone from its current digital platform, TrialTracker, and transplanted it into new innovations.

First adopters

Remember, IXICO is already working with the likely first adopters of this neuroimaging technology – Biogen’s stated aim is to be a pioneer in neuroscience but the platform is likely to be of interest to other major pharmaceuticals companies active in this area.

Why are the multi-national drug giants interested in companion products and willing to shell out for them?

Well, very soon these businesses may be paid on patient outcomes – or good old-fashioned value for money to use more common parlance.

The Biogen collaboration may be in its infancy, but it provides proof positive that IXICO’s strategy has legs.

At 30p, the AIM-listed company is valued at about £14mln.


View full IXI profile View Profile

IXICO Plc Timeline

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use